Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: hold back (279), keep back (403), deny (12)

Brigatinib

Description: Chemotherapy Protocol Lung Cancer Regimen Brigatinib • NSCLC – Brigatinib Indication • Brigatinib is indicated as monotherapy for the treatment of adult pati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Brigatinib.pdf

Binimetinib-Encorafenib

Description: Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or metastatic BRAF V6
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

Enfortumab-Vedotin-Pembrolizumab

Description: Chemotherapy Protocol UROTHELIAL CANCER Enfortumab vedotin-Pembrolizumab (EV-P) Regimen • Urothelial – Enfortumab vedotin - Pembrolizumab Indication • Firs
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Enfortumab-Vedotin-Pembrolizumab.pdf

Atezolizumab-Paclitaxel Albumin Bound

Description: Chemotherapy Protocol BREAST CANCER Atezolizumab-Paclitaxel Albumin Bound Regimen •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Atezolizumab-Paclitaxel-Albumin-Bound.pdf

Atezolizumab (1875mg 21-days) SC

Description: Chemotherapy Protocol UROTHELIAL CANCER Atezolizumab SC (1875mg – 21 days) Regimen • Urothelial cancer – A
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab-SC-1875mg-21-days.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 d
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Erdafitinib

Description: Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or metastatic urothelial
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACL
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

Atezolizumab SC-Carboplatin(AUC5)-Etoposide (IV/PO)

Description: Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-SC-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regim
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-SC-CarboplatinAUC5-Etoposide-IVPO.pdf

1 to 10 of 211

Previous 1 2 3 4 5 … Next